Lataa...
Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context
Immune checkpoint inhibitors (ICIs) have transformed the therapeutic strategy and prognosis of advanced non-small cell lung cancer (NSCLC) patients. Nowadays, ICIs as monotherapy or in combination with chemotherapy are the standard of care treatment in advanced NSCLC, and in stage III, durvalumab (a...
Tallennettuna:
| Julkaisussa: | Onco Targets Ther |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7369644/ https://ncbi.nlm.nih.gov/pubmed/32764980 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S259308 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|